<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01955720</url>
  </required_header>
  <id_info>
    <org_study_id>1321.2</org_study_id>
    <secondary_id>2013-003616-52</secondary_id>
    <nct_id>NCT01955720</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled, Two-way Cross-over Phase Ib Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655075 and to Establish the Efficacy of BI 655075 in Reversal of Dabigatran Anticoagulant Activity in Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate safety, tolerability, PK and PD of BI 655075 and to establish the BI 655075
      dose(s) effective to reverse prolongation of blood coagulation time by dabigatran
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reversal of Dabigatran-induced Prolongation of Blood Coagulation Time</measure>
    <time_frame>End of last infusion and 10 minutes after completion of last infusion of BI 655075</time_frame>
    <description>Percentage of subjects with at least one assay value from diluted thrombin time (dTT) or ecarin clotting time (ECT) reversed within 10min after completion of infusion. Reversal was defined as return to baseline, where the threshold for reversal to baseline was determined using PK/PD correlation between unbound sum dabigatran and the clotting parameters ECT and dTT. Measured at the end of the infusion and 10 min later.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Subjects With Drug-related Adverse Events</measure>
    <time_frame>From baseline up to the start of follow-up period (from Day 1 to Day 35)</time_frame>
    <description>The percentage of subjects with possibly drug-related AEs (as defined by the investigator) during the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (Area Under the Concentration-time Curve of Idarucizumab (Ida) in Plasma Over the Time Interval From 0 Extrapolated to Infinity)</measure>
    <time_frame>From Day 4 to Day 9 (details in description)</time_frame>
    <description>AUC0-infinity. PK/PD sampling time: (p=predose, D=day)
single medium or high dose, healthy subjects(HS) mid-age (45-64 yrs): D4: 8:55p, 9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00; D5: 9:00p, 21:00. D6: 9:00.
single low or high dose, HS elderly or mild renal impaired: D4: 8:55p, 9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00; D5: 9:00; D6: 9:00; D7: 9:00; additional sampling for renal impaired: D8: 9:00;D9: 9:00.
high 2 doses, moderate renal impaired: D4: 8:55p, 9:00, 9:10,9:30,9:55p, 10:00,10:10,10:30,11:00, 13:00, 15:00, 19:00, 21:00, 01:00; D5: 9:00; D6: 9:00; D7: 9:00; additional sampling for renal impaired: D8:9:00; D9:9:00.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC2-12, ss (Area Under the Concentration-time Curve of Unbound Sum Dabigatran (DE) in Plasma at Steady State Over the Time Interval From 2 to 12h)</measure>
    <time_frame>from 2h to12h of post DE dose at steady state (details in description)</time_frame>
    <description>PK/PD sampling time:(d=dose,D=Day,p=predose)
single medium or high dose,healthy, mid-age (45-64 yrs): D4: 7:00p,8:55p,9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00, 01:00; D5:9:00p,11:00,21:00p; D6:9:00p, 21:00p; D7:9:00p, 11:00.
single low or high dose,healthy elder or mild renal impaired: D4:7:00p,8:55p,9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00;D5:9:00;D6:9:00;D7:9:00; additional sampling for renal impaired: D8:9:00;D9:9:00.
high 2 doses, moderate renal impaired: D4:7:00p,8:55p,9:00,9:10,9:30,9:55p,10:00,10:10,10:30,11:00,13:00,15:00,19:00,21:00,01:00;D5:9:00;D6:9:00; D7:9:00; additional sampling for renal impaired: D8:9:00;D9:9:00.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aet1-t2, ss (Amount of DE Eliminated in Urine From the Time Point t1 to Time Point t2)</measure>
    <time_frame>From 0 to 74h post of last DE dose (details in description)</time_frame>
    <description>Urinary excretion of sum dabigatran from the time point t1 to t2 at steady state.
PK Urine sampling time:
Urine sampling relative to first DE administration: Planned times 72:00 - 73:55h, 73:55 - 80:00h, 80:00 - 86:00h, 86:00 - 98:00h, 98:00 - 122:00h, 122:00 - 146:00h; additional sampling for renal impaired: 146:00 - 170:00; 170:00 - 194:00h.
Ae0-26,ss was not measured in Period 3 (re-exposure period). Ae0-74,ss was not measured in healthy subjects aged 45 to 64 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (Maximum Measured Concentration of the Ida in Plasma)</measure>
    <time_frame>From Ida administration to 4 days post dose (details in description)</time_frame>
    <description>Cmax. PK/PD sampling time: (p=predose, D=day)
single medium or high dose, HS mid-age (45-64 yrs): D4: 8:55p, 9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00; D5: 9:00p, 21:00. D6: 9:00.
single low or high dose, healthy elderly or mild RI: D4: 8:55p, 9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00; D5: 9:00; D6: 9:00; D7: 9:00; additional sampling for RI: D8: 9:00;D9: 9:00.
high 2 doses, moderate RI: D4: 8:55p, 9:00, 9:10,9:30,9:55p, 10:00,10:10,10:30,11:00, 13:00, 15:00, 19:00, 21:00, 01:00; D5: 9:00; D6: 9:00; D7: 9:00; additional sampling for RI: D8:9:00; D9:9:00.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae0-6 (Amount of Ida Eliminated in Urine From the Time Point 0 to Time Point 6 h)</measure>
    <time_frame>from 0 to 6 hours of post Ida dose (details in description)</time_frame>
    <description>Ae0-6 (Amount of Ida Eliminated in Urine From the Time Point 0 to Time point 6 h).
PK Urine sampling time:
Urine sampling relative to DE administration: Planned times 72:00 - 73:55h, 73:55 - 80:00h, 80:00 - 86:00h, 86:00 - 98:00h, 98:00 - 122:00h, 122:00 - 146:00h; additional sampling for renal impaired: 146:00 - 170:00; 170:00 - 194:00h.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>healthy subjects aged 45-64</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential Crossover to Placebo or BI 655075</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy elderly subjects aged 65-80 year</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential Crossover to Placebo or BI 655075</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mild renal impairment aged 45-80 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential Crossover to Placebo or BI 655075</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mod renal impairment aged 45-80 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential Crossover to Placebo or BI 655075</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655075</intervention_name>
    <arm_group_label>mild renal impairment aged 45-80 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655075</intervention_name>
    <arm_group_label>healthy subjects aged 45-64</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>mod renal impairment aged 45-80 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655075</intervention_name>
    <arm_group_label>healthy elderly subjects aged 65-80 year</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>healthy subjects aged 45-64</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>healthy elderly subjects aged 65-80 year</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>mild renal impairment aged 45-80 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655075</intervention_name>
    <arm_group_label>mod renal impairment aged 45-80 years</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy midage male and female volunteers, age =45 and =64 years, BMI range: =18.5 and
             =29.9 kg/m2

          -  Healthy elderly male and female volunteers, age =65 and =80 years, BMI range: =18.5
             and = 32 kg/m2

          -  Male and female volunteers with mild renal impairment (CLcrd 60-90 (mL/min)) in
             relatively good health, age =45 and =80 years, BMI range: =18.5 and =32 kg/m2 Moderate
             renal impaired (CLcrd =30 to &lt;60 mL/min according Cockcroft&amp;Gault formula in
             relatively good health, age =45 and =80 years, BMI range: =18.5 and =32 kg/m2

        Exclusion criteria:

          -  Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          -  Any evidence of a clinically relevant concomitant disease (other than mild renal
             impairment in the respective group) A significant disease is defined as a disease
             which in the opinion of the investigator

          -  put the volunteer at risk because of participation in the study

          -  may influence the results of the study

          -  may influence the volunteer¿s ability to participate in the study

          -  is not in a stable condition Diabetic, hypercholesterolemia or hypertensive subjects
             can be entered in this trial if the disease is not significant according to these
             criteria

          -  Surgery of the gastrointestinal tract (except appendectomy)

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts.

          -  Chronic or relevant acute infections

          -  History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1321.2.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2013</study_first_posted>
  <results_first_submitted>November 13, 2015</results_first_submitted>
  <results_first_submitted_qc>January 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2016</results_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>5 Ida / Placebo</title>
          <description>Subjects received dabigatran (DE) 220 mg plus idarucizumab (Ida) 5g followed by dabigatran 220 mg plus placebo 5g (high dose)</description>
        </group>
        <group group_id="P2">
          <title>Placebo / 5 Ida</title>
          <description>Subjects received dabigatran (DE) 220 mg plus placebo 5g followed by dabigatran 220 mg plus Ida 5g (high dose)</description>
        </group>
        <group group_id="P3">
          <title>2.5 Ida / Placebo</title>
          <description>Subjects received dabigatran (DE) 220 mg plus Ida 2.5g followed by dabigatran 220 mg plus placebo 2.5g (medium dose)</description>
        </group>
        <group group_id="P4">
          <title>Placebo / 2.5 Ida</title>
          <description>Subjects received dabigatran (DE) 220 mg plus placebo 2.5g followed by dabigatran 220 mg plus Ida 2.5g (medium dose)</description>
        </group>
        <group group_id="P5">
          <title>1 Ida / Placebo</title>
          <description>Subjects received dabigatran (DE) 220 mg plus Ida 1g followed by dabigatran 220 mg plus placebo 1g (low dose)</description>
        </group>
        <group group_id="P6">
          <title>Placebo / 1 Ida</title>
          <description>Subjects received dabigatran (DE) 220 mg plus placebo 1g followed by dabigatran 220 mg plus Ida 1g (low dose)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Healthy Subjects Aged 45-64</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Healthy Subjects Aged 65-80</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects With Mild Renal Impairment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects With Moderate Renal Impairment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set</population>
      <group_list>
        <group group_id="B1">
          <title>Total Subjects Group</title>
          <description>The total subjects group contains the following sub-groups: high dose (5 g idarucizumab), healthy, aged 45-64 yrs: high dose (5 g idarucizumab), healthy elderly, aged 65-80 yrs: high dose (5 g idarucizumab), mild renal impairment (RI), aged 45-80 yrs: high dose (2.5 g + 2.5 g idarucizumab), with moderate RI, aged 45-80 yrs: medium dose (2.5 g idarucizumab), healthy, aged 45-64 yrs: low dose (1 g idarucizumab), healthy elderly, aged 65-80 yrs: low dose (1 g idarucizumab), with mild RI, aged 45-80 yrs.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.8" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reversal of Dabigatran-induced Prolongation of Blood Coagulation Time</title>
        <description>Percentage of subjects with at least one assay value from diluted thrombin time (dTT) or ecarin clotting time (ECT) reversed within 10min after completion of infusion. Reversal was defined as return to baseline, where the threshold for reversal to baseline was determined using PK/PD correlation between unbound sum dabigatran and the clotting parameters ECT and dTT. Measured at the end of the infusion and 10 min later.</description>
        <time_frame>End of last infusion and 10 minutes after completion of last infusion of BI 655075</time_frame>
        <population>PD Set (PDS): The PDS included all subjects from the TS who had at least 1 evaluable predose and on-treatment coagulation test measurement value for at least 1 coagulation test and who did not have important protocol violation relevant to the evaluation of PD.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>idarucizumab-matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Idarucizumab (Ida)</title>
            <description>Idarucizumab (Ida).</description>
          </group>
        </group_list>
        <measure>
          <title>Reversal of Dabigatran-induced Prolongation of Blood Coagulation Time</title>
          <description>Percentage of subjects with at least one assay value from diluted thrombin time (dTT) or ecarin clotting time (ECT) reversed within 10min after completion of infusion. Reversal was defined as return to baseline, where the threshold for reversal to baseline was determined using PK/PD correlation between unbound sum dabigatran and the clotting parameters ECT and dTT. Measured at the end of the infusion and 10 min later.</description>
          <population>PD Set (PDS): The PDS included all subjects from the TS who had at least 1 evaluable predose and on-treatment coagulation test measurement value for at least 1 coagulation test and who did not have important protocol violation relevant to the evaluation of PD.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at least one time point, dTT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>both time points, dTT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at least one time point, ECT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>both time points, ECT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Subjects With Drug-related Adverse Events</title>
        <description>The percentage of subjects with possibly drug-related AEs (as defined by the investigator) during the treatment period.</description>
        <time_frame>From baseline up to the start of follow-up period (from Day 1 to Day 35)</time_frame>
        <population>Treated Set (TS): All randomised subjects who received at least 1 dose of trial medication were included in the treated set.</population>
        <group_list>
          <group group_id="O1">
            <title>On Treatment Group</title>
            <description>during the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects With Drug-related Adverse Events</title>
          <description>The percentage of subjects with possibly drug-related AEs (as defined by the investigator) during the treatment period.</description>
          <population>Treated Set (TS): All randomised subjects who received at least 1 dose of trial medication were included in the treated set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-infinity (Area Under the Concentration-time Curve of Idarucizumab (Ida) in Plasma Over the Time Interval From 0 Extrapolated to Infinity)</title>
        <description>AUC0-infinity. PK/PD sampling time: (p=predose, D=day)
single medium or high dose, healthy subjects(HS) mid-age (45-64 yrs): D4: 8:55p, 9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00; D5: 9:00p, 21:00. D6: 9:00.
single low or high dose, HS elderly or mild renal impaired: D4: 8:55p, 9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00; D5: 9:00; D6: 9:00; D7: 9:00; additional sampling for renal impaired: D8: 9:00;D9: 9:00.
high 2 doses, moderate renal impaired: D4: 8:55p, 9:00, 9:10,9:30,9:55p, 10:00,10:10,10:30,11:00, 13:00, 15:00, 19:00, 21:00, 01:00; D5: 9:00; D6: 9:00; D7: 9:00; additional sampling for renal impaired: D8:9:00; D9:9:00.</description>
        <time_frame>From Day 4 to Day 9 (details in description)</time_frame>
        <population>Pharmacokinetic Set -Ida (PKS-Ida): included all treated subjects who have received at least 1 dose of idarucizumab and who provided data for at least 1 secondary or other PK endpoint in any treatment period, which was judged as evaluable for PK and was not affected by protocol violations relevant to the statistical evaluation of PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>220 mg/2.5 g HS 45−64 Yrs</title>
            <description>HS mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 2.5g.</description>
          </group>
          <group group_id="O2">
            <title>220 mg/2.5 g HS 45-64 Yrs Re-exposure</title>
            <description>HS mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 2.5g and reexposured Ida in period 3</description>
          </group>
          <group group_id="O3">
            <title>220 mg/5 g HS 45-64 Yrs</title>
            <description>HS mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 5g.</description>
          </group>
          <group group_id="O4">
            <title>220 mg/1 g HS 65-80 Yrs</title>
            <description>HS elderly (65-80 yrs) with dabigatran (DE) 220 mg/Ida 1g.</description>
          </group>
          <group group_id="O5">
            <title>220 mg/5 g HS 65-80 Yrs</title>
            <description>HS elderly (65-80 yrs) with dabigatran (DE) 220 mg/Ida 5g.</description>
          </group>
          <group group_id="O6">
            <title>150 mg/1 g Mild Renal Impairment (RI)</title>
            <description>Mild RI (creatinine clearance [CL] 60-90) with dabigatran (DE) 150 mg/Ida 1g</description>
          </group>
          <group group_id="O7">
            <title>150 mg/5 g Mild RI (CL 60-90)</title>
            <description>Mild RI (CL 60-90) with dabigatran (DE) 150 mg/Ida 5g</description>
          </group>
          <group group_id="O8">
            <title>150 mg /2*2.5 g Moderate RI (CL 30-60)</title>
            <description>Moderate RI (CL 30-60) with dabigatran (DE) 150 mg and were infused 2 doses of each Ida 2.5g, given 1 h apart.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-infinity (Area Under the Concentration-time Curve of Idarucizumab (Ida) in Plasma Over the Time Interval From 0 Extrapolated to Infinity)</title>
          <description>AUC0-infinity. PK/PD sampling time: (p=predose, D=day)
single medium or high dose, healthy subjects(HS) mid-age (45-64 yrs): D4: 8:55p, 9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00; D5: 9:00p, 21:00. D6: 9:00.
single low or high dose, HS elderly or mild renal impaired: D4: 8:55p, 9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00; D5: 9:00; D6: 9:00; D7: 9:00; additional sampling for renal impaired: D8: 9:00;D9: 9:00.
high 2 doses, moderate renal impaired: D4: 8:55p, 9:00, 9:10,9:30,9:55p, 10:00,10:10,10:30,11:00, 13:00, 15:00, 19:00, 21:00, 01:00; D5: 9:00; D6: 9:00; D7: 9:00; additional sampling for renal impaired: D8:9:00; D9:9:00.</description>
          <population>Pharmacokinetic Set -Ida (PKS-Ida): included all treated subjects who have received at least 1 dose of idarucizumab and who provided data for at least 1 secondary or other PK endpoint in any treatment period, which was judged as evaluable for PK and was not affected by protocol violations relevant to the statistical evaluation of PK endpoints.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22200" spread="12.7"/>
                    <measurement group_id="O2" value="20600" spread="10.6"/>
                    <measurement group_id="O3" value="37000" spread="18.4"/>
                    <measurement group_id="O4" value="8560" spread="15.2"/>
                    <measurement group_id="O5" value="43900" spread="18.7"/>
                    <measurement group_id="O6" value="10700" spread="14.1"/>
                    <measurement group_id="O7" value="53100" spread="11.1"/>
                    <measurement group_id="O8" value="67900" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC2-12, ss (Area Under the Concentration-time Curve of Unbound Sum Dabigatran (DE) in Plasma at Steady State Over the Time Interval From 2 to 12h)</title>
        <description>PK/PD sampling time:(d=dose,D=Day,p=predose)
single medium or high dose,healthy, mid-age (45-64 yrs): D4: 7:00p,8:55p,9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00, 01:00; D5:9:00p,11:00,21:00p; D6:9:00p, 21:00p; D7:9:00p, 11:00.
single low or high dose,healthy elder or mild renal impaired: D4:7:00p,8:55p,9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00;D5:9:00;D6:9:00;D7:9:00; additional sampling for renal impaired: D8:9:00;D9:9:00.
high 2 doses, moderate renal impaired: D4:7:00p,8:55p,9:00,9:10,9:30,9:55p,10:00,10:10,10:30,11:00,13:00,15:00,19:00,21:00,01:00;D5:9:00;D6:9:00; D7:9:00; additional sampling for renal impaired: D8:9:00;D9:9:00.</description>
        <time_frame>from 2h to12h of post DE dose at steady state (details in description)</time_frame>
        <population>PKS-DE: The PKS-DE included all treated subjects who have received at least 1 dose of DE and who provided data for at least 1 secondary or further PK endpoint in any treatment period, which was judged as evaluable for PK and was not affected by (important) protocol violations relevant to the statistical evaluation of PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>220 mg/2.5g HS 45−64 Years</title>
            <description>Healthy subjects (HS) mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 2.5g.</description>
          </group>
          <group group_id="O2">
            <title>220 mg/Plc. 2.5g HS 45−64 Years</title>
            <description>Healthy subjects (HS) mid-age (45-64 yrs) with dabigatran (DE) 220 mg/ placebo(plc.) 2.5g.</description>
          </group>
          <group group_id="O3">
            <title>220 mg/2.5g HS 45-64 Yrs Re-exposure</title>
            <description>Healthy subjects (HS) mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 2.5g and reexposured Ida in period 3</description>
          </group>
          <group group_id="O4">
            <title>220 mg/5g HS 45-64 Yrs</title>
            <description>Healthy subjects (HS) mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 5g</description>
          </group>
          <group group_id="O5">
            <title>220 mg/Plc. 5g HS 45-64 Yrs</title>
            <description>Healthy subjects (HS) mid-age (45-64 yrs) with dabigatran (DE) 220 mg/plc. 5g.</description>
          </group>
          <group group_id="O6">
            <title>220 mg/1g HS 65-80 Yrs</title>
            <description>Healthy subjects (HS) elderly (65-80 yrs) with dabigatran (DE) 220 mg/Ida 1g.</description>
          </group>
          <group group_id="O7">
            <title>220 mg/Plc. 1g HS 65-80 Yrs</title>
            <description>Healthy subjects (HS) elderly (65-80 yrs) with dabigatran (DE) 220 mg/plc. 1g.</description>
          </group>
          <group group_id="O8">
            <title>220 mg/5g HS 65-80 Yrs</title>
            <description>Healthy subjects (HS) elderly (65-80 yrs) with dabigatran (DE) 220 mg/Ida 5g.</description>
          </group>
          <group group_id="O9">
            <title>220 mg/Plc. 5g HS 65-80 Yrs</title>
            <description>Healthy subjects (HS) elderly (65-80 yrs) with dabigatran (DE) 220 mg/plc. 5g.</description>
          </group>
          <group group_id="O10">
            <title>150 mg/1g Mild RI (CL 60-90)</title>
            <description>Mild RI (CL 60-90) with dabigatran (DE) 150 mg/Ida 1g</description>
          </group>
          <group group_id="O11">
            <title>150 mg/Plc. 1g Mild RI (CL 60-90)</title>
            <description>Mild RI (CL 60-90) with dabigatran (DE) 150 mg/plc. 1g</description>
          </group>
          <group group_id="O12">
            <title>150 mg/5g Mild RI (CL 60-90)</title>
            <description>Mild RI (CL 60-90) with dabigatran (DE) 150 mg/Ida 5g</description>
          </group>
          <group group_id="O13">
            <title>150 mg/Plc. 5g Mild RI (CL 60-90)</title>
            <description>Mild RI (CL 60-90) with dabigatran (DE) 150 mg/plc. 5g</description>
          </group>
          <group group_id="O14">
            <title>150 mg /2*2.5g Moderate RI (CL 30-60)</title>
            <description>Moderate RI (CL 30-60) with dabigatran (DE) 150 mg and were infused as 2 doses of each Ida 2.5g, given 1 h apart.</description>
          </group>
          <group group_id="O15">
            <title>150 mg /Plc. 2*2.5g Moderate RI (CL 30-60)</title>
            <description>Moderate RI (CL 30-60) with dabigatran (DE) 150 mg and were infused as 2 doses of each plc. 2.5g, given 1 h apart.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC2-12, ss (Area Under the Concentration-time Curve of Unbound Sum Dabigatran (DE) in Plasma at Steady State Over the Time Interval From 2 to 12h)</title>
          <description>PK/PD sampling time:(d=dose,D=Day,p=predose)
single medium or high dose,healthy, mid-age (45-64 yrs): D4: 7:00p,8:55p,9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00, 01:00; D5:9:00p,11:00,21:00p; D6:9:00p, 21:00p; D7:9:00p, 11:00.
single low or high dose,healthy elder or mild renal impaired: D4:7:00p,8:55p,9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00;D5:9:00;D6:9:00;D7:9:00; additional sampling for renal impaired: D8:9:00;D9:9:00.
high 2 doses, moderate renal impaired: D4:7:00p,8:55p,9:00,9:10,9:30,9:55p,10:00,10:10,10:30,11:00,13:00,15:00,19:00,21:00,01:00;D5:9:00;D6:9:00; D7:9:00; additional sampling for renal impaired: D8:9:00;D9:9:00.</description>
          <population>PKS-DE: The PKS-DE included all treated subjects who have received at least 1 dose of DE and who provided data for at least 1 secondary or further PK endpoint in any treatment period, which was judged as evaluable for PK and was not affected by (important) protocol violations relevant to the statistical evaluation of PK endpoints.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="75.7"/>
                    <measurement group_id="O2" value="924" spread="25.6"/>
                    <measurement group_id="O3" value="36.0" spread="125"/>
                    <measurement group_id="O4" value="10.6" spread="11.3"/>
                    <measurement group_id="O5" value="933" spread="39.2"/>
                    <measurement group_id="O6" value="284" spread="66.3"/>
                    <measurement group_id="O7" value="1220" spread="40.0"/>
                    <measurement group_id="O8" value="11.6" spread="23.8"/>
                    <measurement group_id="O9" value="1270" spread="32.8"/>
                    <measurement group_id="O10" value="100" spread="192"/>
                    <measurement group_id="O11" value="929" spread="56.0"/>
                    <measurement group_id="O12" value="10.0" spread="0.0828"/>
                    <measurement group_id="O13" value="876" spread="40.5"/>
                    <measurement group_id="O14" value="10.2" spread="3.95"/>
                    <measurement group_id="O15" value="1440" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aet1-t2, ss (Amount of DE Eliminated in Urine From the Time Point t1 to Time Point t2)</title>
        <description>Urinary excretion of sum dabigatran from the time point t1 to t2 at steady state.
PK Urine sampling time:
Urine sampling relative to first DE administration: Planned times 72:00 - 73:55h, 73:55 - 80:00h, 80:00 - 86:00h, 86:00 - 98:00h, 98:00 - 122:00h, 122:00 - 146:00h; additional sampling for renal impaired: 146:00 - 170:00; 170:00 - 194:00h.
Ae0-26,ss was not measured in Period 3 (re-exposure period). Ae0-74,ss was not measured in healthy subjects aged 45 to 64 years.</description>
        <time_frame>From 0 to 74h post of last DE dose (details in description)</time_frame>
        <population>Pharmacokinetic Set - DE (PKS-DE): The PKS-DE included all treated subjects who have received at least 1 dose of DE and who provided data for at least 1 secondary or further PK endpoint in any treatment period, which was judged as evaluable for PK and was not affected by protocol violations relevant to the statistical evaluation of PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>220 mg/2.5g HS 45−64 Years</title>
            <description>HS mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 2.5g.</description>
          </group>
          <group group_id="O2">
            <title>220 mg/Plc. 2.5g HS 45−64 Years</title>
            <description>HS mid-age (45-64 yrs) with dabigatran (DE) 220 mg/ placebo(plc.) 2.5g.</description>
          </group>
          <group group_id="O3">
            <title>220 mg/2.5g HS 45-64 Yrs Re-exposure</title>
            <description>HS mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 2.5g and reexposured Ida in period 3</description>
          </group>
          <group group_id="O4">
            <title>220 mg/5g HS 45-64 Yrs</title>
            <description>HS mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 5g.</description>
          </group>
          <group group_id="O5">
            <title>220 mg/Plc. 5g HS 45-64 Yrs</title>
            <description>HS mid-age (45-64 yrs) with dabigatran (DE) 220 mg/plc. 5g.</description>
          </group>
          <group group_id="O6">
            <title>220 mg/1g HS 65-80 Yrs</title>
            <description>HS elderly (65-80 yrs) with dabigatran (DE) 220 mg/Ida 1g.</description>
          </group>
          <group group_id="O7">
            <title>220 mg/Plc. 1g HS 65-80 Yrs</title>
            <description>HS elderly (65-80 yrs) with dabigatran (DE) 220 mg/plc. 1g.</description>
          </group>
          <group group_id="O8">
            <title>220 mg/5g HS 65-80 Yrs</title>
            <description>HS elderly (65-80 yrs) with dabigatran (DE) 220 mg/Ida 5g.</description>
          </group>
          <group group_id="O9">
            <title>220 mg/Plc. 5g HS 65-80 Yrs</title>
            <description>HS elderly (65-80 yrs) with dabigatran (DE) 220 mg/plc. 5g.</description>
          </group>
          <group group_id="O10">
            <title>150 mg/1g Mild RI (CL 60-90)</title>
            <description>Mild RI (CL 60-90) with dabigatran (DE) 150 mg/Ida 1g</description>
          </group>
          <group group_id="O11">
            <title>150 mg/Plc. 1g Mild RI (CL 60-90)</title>
            <description>Mild RI (CL 60-90) with dabigatran (DE) 150 mg/plc. 1g</description>
          </group>
          <group group_id="O12">
            <title>150 mg/5g Mild RI (CL 60-90)</title>
            <description>Mild RI (CL 60-90) with dabigatran (DE) 150 mg/Ida 5g</description>
          </group>
          <group group_id="O13">
            <title>150 mg/Plc. 5g Mild RI (CL 60-90)</title>
            <description>Mild RI (CL 60-90) with dabigatran (DE) 150 mg/plc. 5g</description>
          </group>
          <group group_id="O14">
            <title>150 mg /2*2.5g Moderate RI (CL 30-60)</title>
            <description>Moderate RI (CL 30-60) with dabigatran (DE) 150 mg and were infused as 2 doses of each Ida 2.5g, given 1 h apart.</description>
          </group>
          <group group_id="O15">
            <title>150 mg /Plc. 2*2.5g Moderate RI (CL 30-60)</title>
            <description>Moderate RI (CL 30-60) with dabigatran (DE) 150 mg and were infused as 2 doses of each plc. 2.5g, given 1 h apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Aet1-t2, ss (Amount of DE Eliminated in Urine From the Time Point t1 to Time Point t2)</title>
          <description>Urinary excretion of sum dabigatran from the time point t1 to t2 at steady state.
PK Urine sampling time:
Urine sampling relative to first DE administration: Planned times 72:00 - 73:55h, 73:55 - 80:00h, 80:00 - 86:00h, 86:00 - 98:00h, 98:00 - 122:00h, 122:00 - 146:00h; additional sampling for renal impaired: 146:00 - 170:00; 170:00 - 194:00h.
Ae0-26,ss was not measured in Period 3 (re-exposure period). Ae0-74,ss was not measured in healthy subjects aged 45 to 64 years.</description>
          <population>Pharmacokinetic Set - DE (PKS-DE): The PKS-DE included all treated subjects who have received at least 1 dose of DE and who provided data for at least 1 secondary or further PK endpoint in any treatment period, which was judged as evaluable for PK and was not affected by protocol violations relevant to the statistical evaluation of PK endpoints.</population>
          <units>μg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="6"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ae0-26,ss(N=6,6,0,6,6,8,8,8,8,6,6,6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6080" spread="26.5"/>
                    <measurement group_id="O2" value="7460" spread="21.0"/>
                    <measurement group_id="O4" value="7560" spread="47.2"/>
                    <measurement group_id="O5" value="7790" spread="43.9"/>
                    <measurement group_id="O6" value="8490" spread="29.4"/>
                    <measurement group_id="O7" value="8870" spread="41.8"/>
                    <measurement group_id="O8" value="7460" spread="39.6"/>
                    <measurement group_id="O9" value="10600" spread="21.9"/>
                    <measurement group_id="O10" value="5800" spread="39.0"/>
                    <measurement group_id="O11" value="6040" spread="44.7"/>
                    <measurement group_id="O12" value="4020" spread="58.3"/>
                    <measurement group_id="O13" value="6280" spread="38.4"/>
                    <measurement group_id="O14" value="4760" spread="26.7"/>
                    <measurement group_id="O15" value="8880" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae0-74,ss(N=0,0,0,0,0,8,8,8,8,6,6,6,6,6,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">not measured in healthy subjects aged 45 to 64 years.</measurement>
                    <measurement group_id="O2" value="NA">not measured in healthy subjects aged 45 to 64 years.</measurement>
                    <measurement group_id="O4" value="NA">not measured in healthy subjects aged 45 to 64 years.</measurement>
                    <measurement group_id="O5" value="NA">not measured in healthy subjects aged 45 to 64 years.</measurement>
                    <measurement group_id="O6" value="10700" spread="22.0"/>
                    <measurement group_id="O7" value="10300" spread="40.8"/>
                    <measurement group_id="O8" value="13900" spread="26.1"/>
                    <measurement group_id="O9" value="12800" spread="20.6"/>
                    <measurement group_id="O10" value="7760" spread="38.8"/>
                    <measurement group_id="O11" value="7170" spread="45.8"/>
                    <measurement group_id="O12" value="9730" spread="35.3"/>
                    <measurement group_id="O13" value="7690" spread="39.1"/>
                    <measurement group_id="O14" value="11100" spread="24.5"/>
                    <measurement group_id="O15" value="10800" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (Maximum Measured Concentration of the Ida in Plasma)</title>
        <description>Cmax. PK/PD sampling time: (p=predose, D=day)
single medium or high dose, HS mid-age (45-64 yrs): D4: 8:55p, 9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00; D5: 9:00p, 21:00. D6: 9:00.
single low or high dose, healthy elderly or mild RI: D4: 8:55p, 9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00; D5: 9:00; D6: 9:00; D7: 9:00; additional sampling for RI: D8: 9:00;D9: 9:00.
high 2 doses, moderate RI: D4: 8:55p, 9:00, 9:10,9:30,9:55p, 10:00,10:10,10:30,11:00, 13:00, 15:00, 19:00, 21:00, 01:00; D5: 9:00; D6: 9:00; D7: 9:00; additional sampling for RI: D8:9:00; D9:9:00.</description>
        <time_frame>From Ida administration to 4 days post dose (details in description)</time_frame>
        <population>PKS-Ida</population>
        <group_list>
          <group group_id="O1">
            <title>220 mg/2.5 g HS 45−64 Years</title>
            <description>HS mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 2.5g.</description>
          </group>
          <group group_id="O2">
            <title>220 mg/2.5 g HS 45-64 Yrs Re-exposure</title>
            <description>HS mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 2.5g and reexposured Ida in period 3</description>
          </group>
          <group group_id="O3">
            <title>220 mg/5 g HS 45-64 Yrs</title>
            <description>HS mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 5g.</description>
          </group>
          <group group_id="O4">
            <title>220 mg/1 g HS 65-80 Yrs</title>
            <description>HS elderly (65-80 yrs) with dabigatran (DE) 220 mg/Ida 1g.</description>
          </group>
          <group group_id="O5">
            <title>220 mg/5 g HS 65-80 Yrs</title>
            <description>HS elderly (65-80 yrs) with dabigatran (DE) 220 mg/Ida 5g.</description>
          </group>
          <group group_id="O6">
            <title>150 mg/1 g Mild RI (CL 60-90)</title>
            <description>Mild RI (CL 60-90) with dabigatran (DE) 150 mg/Ida 1g</description>
          </group>
          <group group_id="O7">
            <title>150 mg/5 g Mild RI (CL 60-90)</title>
            <description>Mild RI (CL 60-90) with dabigatran (DE) 150 mg/Ida 5g</description>
          </group>
          <group group_id="O8">
            <title>150 mg /2*2.5 g Moderate RI (CL 30-60)</title>
            <description>Moderate RI (CL 30-60) with dabigatran (DE) 150 mg and were infused 2 doses of each Ida 2.5g, given 1 h apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Measured Concentration of the Ida in Plasma)</title>
          <description>Cmax. PK/PD sampling time: (p=predose, D=day)
single medium or high dose, HS mid-age (45-64 yrs): D4: 8:55p, 9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00; D5: 9:00p, 21:00. D6: 9:00.
single low or high dose, healthy elderly or mild RI: D4: 8:55p, 9:00,9:10,9:30,10:00,11:00,13:00,15:00,19:00,21:00,01:00; D5: 9:00; D6: 9:00; D7: 9:00; additional sampling for RI: D8: 9:00;D9: 9:00.
high 2 doses, moderate RI: D4: 8:55p, 9:00, 9:10,9:30,9:55p, 10:00,10:10,10:30,11:00, 13:00, 15:00, 19:00, 21:00, 01:00; D5: 9:00; D6: 9:00; D7: 9:00; additional sampling for RI: D8:9:00; D9:9:00.</description>
          <population>PKS-Ida</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15700" spread="14.3"/>
                    <measurement group_id="O2" value="14900" spread="12.0"/>
                    <measurement group_id="O3" value="25000" spread="16.9"/>
                    <measurement group_id="O4" value="5790" spread="16.4"/>
                    <measurement group_id="O5" value="28300" spread="28.9"/>
                    <measurement group_id="O6" value="6940" spread="19.4"/>
                    <measurement group_id="O7" value="32100" spread="17.4"/>
                    <measurement group_id="O8" value="25600" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ae0-6 (Amount of Ida Eliminated in Urine From the Time Point 0 to Time Point 6 h)</title>
        <description>Ae0-6 (Amount of Ida Eliminated in Urine From the Time Point 0 to Time point 6 h).
PK Urine sampling time:
Urine sampling relative to DE administration: Planned times 72:00 - 73:55h, 73:55 - 80:00h, 80:00 - 86:00h, 86:00 - 98:00h, 98:00 - 122:00h, 122:00 - 146:00h; additional sampling for renal impaired: 146:00 - 170:00; 170:00 - 194:00h.</description>
        <time_frame>from 0 to 6 hours of post Ida dose (details in description)</time_frame>
        <population>PKS-Ida: The PKS-Ida included all treated subjects who have received at least 1 dose of idarucizumab and who provided data for at least 1 secondary or other PK endpoint in any treatment period, which was judged as evaluable for PK and was not affected by (important) protocol violations relevant to the statistical evaluation of PK endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>220 mg/2.5 g HS 45−64 Years</title>
            <description>HS mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 2.5g.</description>
          </group>
          <group group_id="O2">
            <title>220 mg/2.5 g HS 45-64 Yrs Re-exposure</title>
            <description>HS mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 2.5g and reexposured Ida in period 3</description>
          </group>
          <group group_id="O3">
            <title>220 mg/5 g HS 45-64 Yrs</title>
            <description>HS mid-age (45-64 yrs) with dabigatran (DE) 220 mg/Ida 5g.</description>
          </group>
          <group group_id="O4">
            <title>220 mg/1 g HS 65-80 Yrs</title>
            <description>HS elderly (65-80 yrs) with dabigatran (DE) 220 mg/Ida 1g.</description>
          </group>
          <group group_id="O5">
            <title>220 mg/5 g HS 65-80 Yrs</title>
            <description>HS elderly (65-80 yrs) with dabigatran (DE) 220 mg/Ida 5g.</description>
          </group>
          <group group_id="O6">
            <title>150 mg/1 g Mild RI (CL 60-90)</title>
            <description>Mild RI (CL 60-90) with dabigatran (DE) 150 mg/Ida 1g</description>
          </group>
          <group group_id="O7">
            <title>150 mg/5 g Mild RI (CL 60-90)</title>
            <description>Mild RI (CL 60-90) with dabigatran (DE) 150 mg/Ida 5g</description>
          </group>
          <group group_id="O8">
            <title>150 mg /2*2.5 g Moderate RI (CL 30-60)</title>
            <description>Moderate RI (CL 30-60) with dabigatran (DE) 150 mg and were infused 2 doses of each Ida 2.5g, given 1 h apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae0-6 (Amount of Ida Eliminated in Urine From the Time Point 0 to Time Point 6 h)</title>
          <description>Ae0-6 (Amount of Ida Eliminated in Urine From the Time Point 0 to Time point 6 h).
PK Urine sampling time:
Urine sampling relative to DE administration: Planned times 72:00 - 73:55h, 73:55 - 80:00h, 80:00 - 86:00h, 86:00 - 98:00h, 98:00 - 122:00h, 122:00 - 146:00h; additional sampling for renal impaired: 146:00 - 170:00; 170:00 - 194:00h.</description>
          <population>PKS-Ida: The PKS-Ida included all treated subjects who have received at least 1 dose of idarucizumab and who provided data for at least 1 secondary or other PK endpoint in any treatment period, which was judged as evaluable for PK and was not affected by (important) protocol violations relevant to the statistical evaluation of PK endpoints.</population>
          <units>umol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="32.6"/>
                    <measurement group_id="O3" value="33.5" spread="60.0"/>
                    <measurement group_id="O4" value="1.97" spread="69.0"/>
                    <measurement group_id="O5" value="41.6" spread="13.7"/>
                    <measurement group_id="O6" value="2.60" spread="46.7"/>
                    <measurement group_id="O7" value="33.4" spread="48.9"/>
                    <measurement group_id="O8" value="31.3" spread="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the study drug administration up to start of follow-up period (from Day 1 to Day 35).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran Etexilate (DE)</title>
          <description>subjects with Dabigatran etexilate (DE) treatment</description>
        </group>
        <group group_id="E2">
          <title>Low (1g) Idarucizumab Dose</title>
          <description>Subjects with low 1g idarucizumab dose treatment</description>
        </group>
        <group group_id="E3">
          <title>Medium (2.5g) Idarucizumab Dose</title>
          <description>Subjects with medium (2.5g) idarucizumab dose treatment</description>
        </group>
        <group group_id="E4">
          <title>High (5g) Idarucizumab Dose</title>
          <description>Subjects with high (5g) idarucizumab dose treatment</description>
        </group>
        <group group_id="E5">
          <title>Low (1g) Placebo Dose</title>
          <description>Subjects with low (1g) placebo dose treatment</description>
        </group>
        <group group_id="E6">
          <title>Medium (2.5g) Placebo Dose</title>
          <description>Subjects with medium (2.5g) placebo dose treatment</description>
        </group>
        <group group_id="E7">
          <title>High (5g) Placebo Dose</title>
          <description>Subjects with high (5g) placebo dose treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

